Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
about
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSGlycogen synthase kinase 3: more than a namesakeSilencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's miceScreening marine resources to find novel chemical inhibitors of disease-relevant protein kinasesA Novel Approach to the Discovery of Small-Molecule Ligands of CDK2Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity.Synthesis and biological evaluation of thienopyrrolizines, a new family of CDK/GSK-3 inhibitors.A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screeningStructure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.Small-molecule cyclin-dependent kinase modulators.Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?Targeting low molecular weight cyclin E (LMW-E) in breast cancer.Selective inhibition of proteins regulating CDK/cyclin complexes: strategy against cancer--a review.Silencing of CDK5 as potential therapy for Alzheimer's disease.Tau as a therapeutic target for Alzheimer's diseaseRepairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator.Personalized Medicine and Resurrected Hopes for the Management of Alzheimer's Disease: A Modular Approach Based on GSK-3β Inhibitors.Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal.Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors.Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates.Quantitative Structure-Activity Relationship Analysis and a Combined Ligand-Based/Structure-Based Virtual Screening Study for Glycogen Synthase Kinase-3.Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu miceStructure-aided optimization of kinase inhibitors derived from alsterpaullone.Stimulation of Wild-Type, F508del- and G551D-CFTR Chloride Channels by Non-Toxic Modified pyrrolo[2,3-b]pyrazine Derivatives.Azaindole synthesis through dual activation catalysis with N-heterocyclic carbenes.Development of an assay to screen for inhibitors of tau phosphorylation by cdk5.Research advances in kinase enzymes and inhibitors for cardiovascular disease treatment.Exposure to pyrithiamine increases β-amyloid accumulation, Tau hyperphosphorylation, and glycogen synthase kinase-3 activity in the brain.Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.General Purpose Electronegativity Relaxation Charge Models Applied to CoMFA and CoMSIA Study of GSK-3 Inhibitors.
P2860
Q21129334-45B5EEBE-9122-4B6C-AC1D-1290E6470672Q24315635-9489F190-5760-4C17-A849-5DEFB1658BD8Q24628256-D4593FAA-7798-4207-9452-12879FC2DE3BQ27026168-F83B2DEE-6458-490A-BB93-B5B609F8F3CFQ27671549-68BF1366-8E7E-4935-B8C5-CBBAAD655350Q31098941-8E5CBCE8-59FB-4757-9A7E-B19D5F0B1A52Q33211084-672D965D-AE7E-40E3-BCD7-369F0762060BQ34582206-4CF485AC-EBAA-4F97-9829-4C799907C087Q34625383-4BF68293-4D3F-4F21-B6AA-20269322A848Q34706737-9D98183C-BB4B-40D4-9809-64D6D43C0F70Q35551149-2CD39B5F-91E5-47FE-AC4C-26E251C81396Q37198579-955C98D0-6CEF-4C57-B761-1F8517342A52Q37373562-2D8F4206-6247-46BC-B079-67438A410406Q37766226-263BBE9A-5FF1-467F-8EBE-B3F88FFE4E6AQ37863144-B290C8B9-47F8-4BAB-8615-E35B0F65C58EQ37890451-0FA40E9A-2C3B-48DA-90A1-3B9E38B9C69DQ38097952-F0D24833-444F-4699-B1C2-5FCEE191197EQ38608683-22B939FA-D82D-4918-B7AF-65643080C11BQ38994300-8213D255-A47D-4A9E-A413-D75D4E91B539Q39008696-91EA343F-99AC-4075-B3F1-061C9A3C1EABQ39393192-1E0B6CCD-57D2-4747-B6DD-C09B5FD27F35Q39530733-5612D23C-2018-48CC-A4AC-A00899C4F068Q40444868-9579E89B-0CFF-4A7C-B4C4-441DA08DE873Q40461072-AA7314EB-E5D5-4848-B98A-B8DCA88C5590Q42011265-2FB5DCBA-6B43-43D5-BDA7-90EAAEFAD558Q42036367-F2303130-6315-45E7-9B23-8149E4A4B057Q44789917-83D6838B-35E6-4F8C-84C9-694BB84BDEE2Q47121794-FD4E836D-6F05-46BD-ADB2-08EB1E1E18B7Q48157530-83D78333-9683-436C-86AC-952F1F8A93D4Q51930326-A779348B-3E06-40DD-9C83-C596D45971F0Q54605338-15FA64CA-EA90-40A0-9658-272054EFFE58
P2860
Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Aloisines, a new family of CDK ...... ctivity, and cellular effects.
@ast
Aloisines, a new family of CDK ...... ctivity, and cellular effects.
@en
type
label
Aloisines, a new family of CDK ...... ctivity, and cellular effects.
@ast
Aloisines, a new family of CDK ...... ctivity, and cellular effects.
@en
prefLabel
Aloisines, a new family of CDK ...... ctivity, and cellular effects.
@ast
Aloisines, a new family of CDK ...... ctivity, and cellular effects.
@en
P2093
P356
P1476
Aloisines, a new family of CDK ...... ctivity, and cellular effects.
@en
P2093
Irène Ceballos-Picot
Jane Endicott
Jean-michel Vierfond
Laurent Meijer
Marie Gompel
Maryse Leost
Virginie Thomas
Yvette Mettey
P304
P356
10.1021/JM020319P
P407
P577
2003-01-01T00:00:00Z